← Back to home

PATIENTS WITH PRIMARY HPV HIGH-GRADE SQUAMOUS INTRA-EPITHELIAL LESIONS (HSIL) AT VULVAR SITE

Clinical trials for PATIENTS WITH PRIMARY HPV HIGH-GRADE SQUAMOUS INTRA-EPITHELIAL LESIONS (HSIL) AT VULVAR SITE explained in plain language.

Never miss a new study

Get alerted when new PATIENTS WITH PRIMARY HPV HIGH-GRADE SQUAMOUS INTRA-EPITHELIAL LESIONS (HSIL) AT VULVAR SITE trials appear

Sign up with your email to follow new studies for PATIENTS WITH PRIMARY HPV HIGH-GRADE SQUAMOUS INTRA-EPITHELIAL LESIONS (HSIL) AT VULVAR SITE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Can a vaccine stop precancerous lesions from returning?

Prevention Not yet recruiting

This study aims to find out if the 9-valent HPV vaccine can prevent high-grade, precancerous lesions from coming back after they have been treated. It will involve about 984 patients aged 18-55 who have recently been treated for these HPV-related lesions. Participants will be ran…

Matched conditions: PATIENTS WITH PRIMARY HPV HIGH-GRADE SQUAMOUS INTRA-EPITHELIAL LESIONS (HSIL) AT VULVAR SITE

Phase: PHASE3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Prevention

Last updated Apr 01, 2026 14:42 UTC

PATIENTS WITH PRIMARY HPV HIGH-GRADE SQUAMOUS INTRA-EPITHELIAL LESIONS (HSIL) AT VULVAR SITE

Get alerted when new PATIENTS WITH PRIMARY HPV HIGH-GRADE SQUAMOUS INTRA-EPITHELIAL LESIONS (HSIL) AT VULVAR SITE trials appear

Can a vaccine stop precancerous lesions from returning?